How a Dedicated Care Team Can Make Participants Feel Safer Meet Becca Kacanda, @beccakacanda.bsky.social a trial participant in MDMA-assisted therapy for PTSD. She shares how the care she received felt different from standard therapy. #PsychedelicResearch #PatientSafety #ClinicalTrials

Are you a clinician, therapist, researcher, QA, program lead, or study staff? Discover how to leverage lived experience as quality and safety infrastructure in psychedelic care. 🗓 Apr 11, 2026 • 10 AM PT / 1 PM ET / 17:00 UTC (19:00 Central Europe) #psychedelics #PatientSafety #LivedExperience

What Makes a Competent Psychedelic Therapist Beyond Degrees Meet Matthew Johnson, PhD, psychedelic researcher, experimental psychologist, senior investigator, and professor at Johns Hopkins University. #Psychedelics #PsychedelicResearch #PatientCenteredCare

Lived experience is not only about sharing stories. It can reveal blind spots, improve quality and safety, and lead to better decisions in research and care. The question is whether the field is willing to treat it as expertise, not just perspective. #Psychedelics #LivedExperience #ClinicalTrials

What Placebo Can Cost Participants in Prolonged Crossover Trials Meet Kathy Neustadt, a clinical trial participant who received placebo in an MDMA-assisted therapy research for PTSD. #PsychedelicTherapy #PsychedelicResearch #PatientSafety #ClinicalTrials #placeboeffect

Lived experience may be welcomed into the conversation, but rarely trusted with real authority. That gap matters. Because inclusion is not the same as influence, and consultation is not the same as shared decision-making. #Psychedelics #LivedExperienceExpertise #ClinicalTrials

Upcoming workshop: Apr 11, 2026 • 10 AM PT / 1 PM ET / 17:00 UTC (19:00 Central Europe) Discover how to leverage lived experience as quality and safety infrastructure in psychedelic care. #PsychedelicTherapy #PsychedelicResearch #PatientSafety #LivedExperience #ClinicalTrials

In 2023, the FDA issued draft guidance on clinical investigations for psychedelic drugs. The document says it is meant to give sponsors general considerations for developing psychedelic drugs for medical conditions, including trial conduct, data collection, and subject safety. #Psychedelics #FDA

When Lived Experience Is Shared on Stage, Safety Matters Meet Joost Breeksema, PhD, a qualitative researcher in psychedelic trials and Executive Director of the OPEN Foundation in the Netherlands, which organizes the ICPR conference (June 4-6, 2026). #Psychedelics #PsychedelicResearch

In psychedelic care, safety is often about the dosing day. If we want a more honest standard, safety cannot mean only “nothing visibly went wrong during treatment.” It has to include what happens after, when real life resumes. #PsychedelicResearch #PatientSafety #ClinicalTrials #Psychedelics

Psilocybin Therapy for Anxiety: Building Safety and Trust Before Dosing Leonie reflects on what helped her feel safe entering the trial and what built trust before dosing. She shares how preparation played an important role in creating a greater sense of safety. #Psychedelics #Psilocybin

In psychedelic care, safety is often framed around screening, dosing, supervision, and acute adverse events. Those matter. But they are not the whole picture. If safety only means “nothing visibly went wrong in the room,” the standard is too low. #Psychedelics #PatientSafety

Joining this workshop? Lived Experience as Quality and Safety Infrastructure in Psychedelic Care 🗓 Apr 11, 2026 • 10 AM PT / 1 PM ET / 17:00 UTC If you’re a clinician/therapist, researcher, QA, program lead, or study staff, this is for you. #PsychedelicTherapy #PsychedelicResearch #Psychedelics

Eligibility criteria are necessary. They help ensure safety, consistency, and rigor in research. But they also simplify. People don’t arrive as clean variables. They arrive with overlapping histories, contexts, and contradictions. #PsychedelicResearch #PatientCenteredCare #Psychedelics

Why Individual Treatment May Not Be Enough in Psychedelic Care Meet Chris Stauffer, MD, psychiatrist, addiction medicine specialist, and investigator of group MDMA therapy for veterans with PTSD. #PsychedelicTherapy #PsychedelicResearch #PeerSupport #LivedExperience #MDMAtherapy

Live workshop — Apr 11, 2026. Lived Experience as Quality and Safety Infrastructure in Psychedelic Care Frameworks + checklist to integrate lived experience into research and care (without tokenism). No Professional Pass yet? Get one to join. Link in bio. #psychedelics #PatientSafety

What Being Taken Off the Clinical Trial Really Felt Like Meet Kerrilee Barrett, a mental health practitioner who participated in a clinical trial involving a psychoactive substance for PTSD. #PsychedelicTherapy #PsychedelicResearch #PatientCenteredCare #LivedExperience #Psychedelics

For decades, mental health innovation has claimed to include the voices of people with lived experience. But how much influence do those voices actually have? Paper: mental.jmir.org/2023/1/e46590 #MentalHealthResearch #PatientCenteredCare #LivedExperience #MentalHealthInnovation

Ibogaine Care and Why Lived Experience Matters Meet Jonathan Dickinson, a psychologist, renowned Ibogaine expert, published researcher, and CEO & co-founder at Ambio Life Sciences. #PsychedelicTherapy #PsychedelicResearch #LivedExperience #Ibogaine #Iboga #Psychedelics

Psychedelic clinical trials often focus on symptom reduction. That matters, but it is not the full story. A participant can look improved on a clinical scale while still struggling with stability, relationships, meaning-making, or life after the protocol ends. #PsychedelicResearch #ClinicalTrials

How Psilocybin Therapy Changed the Way I Process Emotions Meet Daryna Skybina, MPS who participated in a clinical trial studying psilocybin-assisted therapy for people with advanced cancer. #PsychedelicTherapy #PsychedelicResearch #LivedExperience #CancerResearch #PatientVoices #Psychedelics

Safety in psychedelic care cannot rely only on protocols, clinical training, or symptom scores. The people who go through these treatments often see risks, challenges, and gaps that formal systems miss. #PsychedelicTherapy #PsychedelicResearch #PatientCenteredCare #LivedExperience #Psychedelics

Are Psychedelic Experiences Just Brain Activity? Bill reflects on a debate between Guy Goodwin and Max Wolff @trpwolff.bsky.social where it was suggested what people say about their experiences may be a kind of smokescreen and that the real explanation lies only in what is happening in the brain.

Psychedelic clinical trials measure important outcomes. But the people who go through these experiences often see dimensions of healing and challenge that standard frameworks miss. #PsychedelicTherapy #PsychedelicResearch #PatientCenteredCare #LivedExperience #PsychedelicScience

Psilocybin Therapy for Depression Can Be Both Healing and Destabilizing Meet Heather Joy, a clinical trial participant in an open-label psilocybin-assisted therapy study for treatment-resistant depression. #PsychedelicTherapy #PsychedelicResearch #Psilocybin #Psychedelics

In psychedelic research, improvement is often measured through symptom scales. MADRS scores drop. CAPS scores decrease. PHQ-9 improves. GAD-7 declines. That matters. But participants often struggle with: Identity. Relationships. Career. Spiritual. Stability. #Psychedelics

Destigmatization, Legalization, and Why Clear Rules Protect Patients Meet Janina Kowalski, MD, a psychiatrist who underwent ketamine, MDMA, LSD, and psilocybin in experiential therapist training. #PsychedelicTherapy #PsychedelicResearch #PatientCenteredCare #PsychedelicScience

A psychedelic integration therapy session might last 60 minutes. Integration itself can last months, maybe years. Clinical care is essential. But transformation doesn’t confine to calendar blocks. This is why lived experience matters in how we design care. #Psychedelics

Beyond Lip Service: Meaningful Inclusion of Lived Experience Meet Simon Amar, MD, a psychiatrist and investigator for MDMA for PTSD and psilocybin for anxiety clinical trials #PsychedelicTherapy #PsychedelicResearch #PatientCenteredCare #LivedExperience #PsychedelicScience #Psychedelics

Psychedelic clinical trial participants contribute more than data. They contribute time. Vulnerability. Personal history. Emotional labor. In most cases, they are not systematically informed when results are published, or engaged in how findings are interpreted. #Psychedelics

MDMA-Assisted Therapy Trial: Safety, Trust, and Returning to Work Meet Sehrish Sayani, who participated in a Phase 3 MDMA-assisted therapy clinical trial for PTSD. #PsychedelicTherapy #PsychedelicResearch #PatientCenteredCare #LivedExperience #PsychedelicScience #Psychedelics

William James helped lay the foundations of modern psychology. And yet his insight still challenges us: What we choose to attend to shapes what we call knowledge. #PsychedelicTherapy #PsychedelicResearch #PatientCenteredCare #LivedExperience #PsychedelicScience #Psychedelics

The Importance of Sharing Nuanced and Difficult Psychedelic Experiences Meet Will Barone, Psy.D, a clinical psychologist and qualitative researcher in studies with MDMA, psilocybin, & ketamine #PsychedelicTherapy #PsychedelicResearch #LivedExperience #PsychedelicScience

Psychedelic clinical research is advancing rapidly. While it’s optimizing for measurable outcomes, many participants describe changes that don’t fit neatly into a scale. If we want safer and more durable models of care, lived experience must become structural. #Psychedelics

Inside Group Ketamine-Assisted Therapy: A Firsthand Experience Meet Jana Sladkova, PhD, who participated in a group ketamine-assisted therapy program for depression. #PsychedelicTherapy #PsychedelicResearch #PatientCenteredCare #LivedExperience #PsychedelicScience #Psychedelics

The psychedelic field is producing more data than ever. More trials. More publications. More outcome measures. Lived experience isn’t missing because it lacks insight. It’s missing because we haven’t structurally prioritized listening. #PsychedelicTherapy #PsychedelicResearch #Psychedelics

Music in Psychedelic Trials: Insights from a Delphi Study Meet Chloé Pronovost-Morgan, MD, MSc, psychiatry resident and lead author of a Delphi study focused on “set and setting” in psychedelic trials. #PsychedelicTherapy #PsychedelicResearch #PatientCenteredCare #LivedExperience #Psychedelics

When the six-month follow-up interview comes around and they ask about symptom changes... #PsychedelicTherapy #PsychedelicResearch #PatientCenteredCare #LivedExperience #PsychedelicScience

Fear Processing in MDMA-Assisted Therapy: A Patient Perspective Meet Frank Sers from Switzerland who received MDMA and LSD-assisted therapies for depression via compassionate use. #PsychedelicTherapy #PsychedelicResearch #PatientCenteredCare #LivedExperience #PsychedelicScience

Psychedelic research relies on validated scales to measure outcomes: depression scores, PTSD symptoms, anxiety levels. But participants describe changes not fitting into a questionnaire: identity shifts, relationship changes, spiritual insights, destabilization, renewed purpose. #Psychedelics

Meaning Making Intervention in Psychedelic Prep Sessions Meet Julia King Olivier, MD — psychiatrist, psychedelic therapist, and founder of the Compassionate Care Center in Geneva, Switzerland. #PsychedelicTherapy #PsychedelicResearch #PatientCenteredCare #LivedExperience #PsychedelicScience

This is what it looks like when a community prioritizes access and inclusion. Through a grassroots and unfunded effort, and with the generosity of some attendees, we welcomed many people who otherwise would not have been able to fully take part in the summit. #Psychedelics

Why Lived Experience Perspectives Are Often Missing from Psychedelic Research Conversations Meet Sandeep Nayak, MD, a psychiatrist, psilocybin clinical researcher, and associate professor at Johns Hopkins University @jhpsychedelics.bsky.social. #PsychedelicResearch #Psychedelics

When we talk about safety in psychedelic care, we often focus on protocols, screening, and clinical oversight. Patients tell a broader story. Feeling safe means being trusted, prepared, supported, and not left alone once the session ends. #livedexperience #psychedelics

Do you work in psychedelic clinical research? In this short Behind the Scenes Update (Dec 20, 2025), our founder and director, Pedram Dara @pedramdara.bsky.social, shares how a new initiative is taking shape following conversations from the first-ever Psychedelic Lived Experiences Summit.

When the follow-up Zoom call asks: “Any adverse events?” (and you don’t know where your life fits on the checklist) #Psychedelics #LivedExperience #ClinicalResearch #clinicaltrials #patientadvocacy #mentalhealth #memes

Rethinking Safety in Psychedelic Care for Cancer Patients Meet Anne Hamilton, founder & executive director of The Survivorship Collective, a nonprofit focused on support related to legal psychedelic-assisted care for people affected by cancer. #CancerSurvivorship #HealingJourneys #psychedelics

For everything the psychedelic-assisted therapy field is still working to improve, there are three strengths that already stand out. These strengths offer meaningful foundations for the future. Learn more below and share what you think. #psychedelics #livedexperience

Behind the Scenes Update | Dec 13, 2025 In this short update, our founder & director Pedram Dara, @pedramdara.bsky.social shares reflections on what has been happening behind the scenes in the psychedelic research and education space over the past few weeks. #LivedExperience #Psychedelics

Psychedelic-assisted therapy research shows promise because it supports reflection, connection, and new perspectives. Lived experience inputs remind us that participant journeys are complex and rarely follow a single path. #Psychedelics #ClinicalResearch #PatientAdvocacy #LivedExperience